Jane Street’s Alder Biopharmaceuticals ALDR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-301,621
Closed -$5.69M 6167
2019
Q3
$5.69M Buy
+301,621
New +$3.45M 0.01% 903
2018
Q1
Sell
-16,169
Closed -$185K 5734
2017
Q4
$185K Buy
16,169
+1,109
+7% +$12.4K ﹤0.01% 4242
2017
Q3
$184K Buy
+15,060
New +$157K ﹤0.01% 4157
2016
Q4
Sell
-10,124
Closed -$332K 4860
2016
Q3
$332K Buy
+10,124
New +$308K ﹤0.01% 3202
2016
Q2
Sell
-48,823
Closed -$1.2M 4839
2016
Q1
$1.2M Buy
+48,823
New +$1.13M 0.01% 1690
2015
Q4
Sell
-6,189
Closed -$203K 4672
2015
Q3
$203K Sell
6,189
-10,524
-63% -$447K ﹤0.01% 3177
2015
Q2
$885K Buy
+16,713
New +$608K 0.01% 1691

Jane Street's ALDR Position: Q4 2019 in Review

Jane Street sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 301,621 shares — an estimated $5.69M sold.

Jane Street first reported a position in ALDR in Q2 2015 and held it in 7 quarters. The position peaked at $5.69M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

  • Jane Street reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Jane Street sold 301,621 Alder Biopharmaceuticals shares in Q4 2019, an estimated $5.69M.
  • Jane Street first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 7 quarters.
  • Jane Street's Alder Biopharmaceuticals position peaked at $5.69M in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Jane Street's 13F filing for Q4 2019, filed 14 Feb 2020.